X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2014) 2014
Publication (189) 189
Book Review (26) 26
Book Chapter (5) 5
Conference Proceeding (2) 2
Data Set (2) 2
Magazine Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1426) 1426
sofosbuvir (1291) 1291
humans (1283) 1283
hepatitis c (1141) 1141
hepatitis c virus (1008) 1008
ribavirin (937) 937
gastroenterology & hepatology (864) 864
antiviral agents - therapeutic use (852) 852
hepatitis c, chronic - drug therapy (797) 797
male (706) 706
hepatitis (693) 693
female (678) 678
interferon (666) 666
middle aged (646) 646
hepacivirus - genetics (584) 584
genotype (562) 562
drug therapy, combination (538) 538
treatment outcome (499) 499
antiviral agents (488) 488
cirrhosis (469) 469
ledipasvir (455) 455
hcv (448) 448
adult (419) 419
health aspects (407) 407
infection (407) 407
aged (406) 406
therapy (388) 388
virus-infection (380) 380
liver (375) 375
patients (361) 361
hepatitis c - drug therapy (350) 350
sustained virological response (347) 347
hepacivirus - drug effects (345) 345
infections (344) 344
ribavirin - therapeutic use (341) 341
antiviral agents - administration & dosage (336) 336
care and treatment (329) 329
infectious diseases (321) 321
liver cirrhosis (308) 308
sofosbuvir - therapeutic use (308) 308
hepatitis c, chronic - virology (305) 305
drug therapy (304) 304
antiviral agents - adverse effects (300) 300
genotype 1 infection (299) 299
pharmacology & pharmacy (298) 298
daclatasvir (291) 291
analysis (287) 287
genotype & phenotype (280) 280
treatment-naive patients (272) 272
genotype 1 (257) 257
sustained virologic response (254) 254
biological response modifiers (252) 252
virology (237) 237
simeprevir (236) 236
viruses (236) 236
direct-acting antivirals (230) 230
plus ribavirin (230) 230
genotypes (223) 223
liver transplantation (220) 220
virus diseases (219) 219
sofosbuvir plus ribavirin (216) 216
genetic aspects (215) 215
transplantation (211) 211
hepatology (209) 209
open-label (208) 208
pegylated interferon (206) 206
uridine monophosphate - analogs & derivatives (192) 192
hcv infection (187) 187
hepatitis c, chronic - complications (186) 186
hepatitis-c virus (184) 184
treatment-naive (183) 183
liver diseases (178) 178
ribavirin - administration & dosage (174) 174
medical research (170) 170
sofosbuvir - administration & dosage (167) 167
antiviral therapy (165) 165
gastroenterology and hepatology (165) 165
efficacy (162) 162
retrospective studies (150) 150
telaprevir (149) 149
combination (148) 148
chronic hepatitis-c (147) 147
young adult (147) 147
medicine, experimental (144) 144
clinical trials (143) 143
hepatitis c - virology (143) 143
fibrosis (142) 142
medicine & public health (142) 142
safety (142) 142
abridged index medicus (141) 141
chronic infection (140) 140
daclatasvir plus sofosbuvir (140) 140
medicine, general & internal (138) 138
hepacivirus (137) 137
uridine monophosphate - therapeutic use (137) 137
immunology (135) 135
recurrence (135) 135
research (134) 134
plus sofosbuvir (132) 132
viral load (132) 132
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1974) 1974
Korean (15) 15
German (10) 10
Spanish (9) 9
French (4) 4
Hungarian (2) 2
Japanese (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 34 - 44
In this small, preliminary study of sofosbuvir, a nucleotide inhibitor of HCV polymerase, treatment with sofosbuvir and ribavirin, without peginterferon, was... 
GENOTYPE 1 | PSI-7977 | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | THERAPY | REPLICATION | RESISTANCE | REPLICON RNA-SYNTHESIS | COMBINATION | TREATMENT-NAIVE PATIENTS | PROTEASE | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Adult | Female | RNA, Viral - metabolism | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hemoglobins - metabolism | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Sofosbuvir | Drugs | Dose-response relationship (Biochemistry) | Antiviral agents | Usage | Patient outcomes | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Interferon | Infections | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
JOURNAL OF HEPATOLOGY, ISSN 0168-8278, 05/2015, Volume 62, Issue 5, pp. 1040 - 1046
Background & Aims: We conducted an open-label phase 2 study to assess the efficacy and safety of the oral nucleotide polymerase inhibitor sofosbuvir in... 
TREATMENT-NAIVE | THERAPY | Direct-acting antiviral | Egyptian | Hepatitis C virus | GASTROENTEROLOGY & HEPATOLOGY | Sofosbuvir | Interferon-free therapy | EPIDEMIOLOGY | Genotype 4
Journal Article
Journal Article
Journal of Viral Hepatitis, ISSN 1352-0504, 11/2014, Volume 21, Issue 11, pp. 762 - 768
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1098 - 1106
Journal Article
Gastroenterology, ISSN 0016-5085, 2015, Volume 149, Issue 6, pp. 1462 - 1470
Journal Article
Journal Article
DIGESTIVE DISEASES AND SCIENCES, ISSN 0163-2116, 05/2018, Volume 63, Issue 5, pp. 1341 - 1347
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). However,... 
OMBITASVIR/PARITAPREVIR/RITONAVIR | VOXILAPREVIR | Ritonavir | 1B INFECTION | Egyptian patients | HCV INFECTION | Ribavirin | REAL-WORLD EFFECTIVENESS | SUSTAINED VIROLOGICAL RESPONSE | VELPATASVIR | Ombitasvir | DASABUVIR | Paritaprevir | GASTROENTEROLOGY & HEPATOLOGY | Sofosbuvir | EPIDEMIOLOGY
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2017, Volume 64, Issue 11, pp. 1615 - 1618
Journal Article
Antiviral Research, ISSN 0166-3542, 12/2016, Volume 136, pp. 37 - 44
Journal Article